en · de · es · pt
handling-notes.peptides9000.com › Blog › Receptor Pharmacology And Mechanism — Quick Reference

Receptor Pharmacology And Mechanism — Quick Reference

By Editorial Desk · published 2025-08-26 · last reviewed 2025-10-04 · Blog

lactam bridge raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.

Receptor Pharmacology And Mechanism

Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.

How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.

Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.

Analytical Methods and Storage Practice

Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.

Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.

Pt-141 at a glance

PropertyValueNotes
Primary receptor targetMC4R agonistSubtype most often linked to behavioural effects
Other reported targetsMC1R, MC3R, MC5RActivity is not selective for a single subtype
Endogenous ligand classMelanocortin peptidesAlpha-MSH and ACTH act on the same family
Peptide architectureCyclic heptapeptideLactam bridge between the aspartate and lysine residues
Central actionInferred from animal modelsNot directly measured in the human brain

Identity and Chemical Background

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

Related pages on this site

Chemical Identity of Bremelanotide

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.

Receptor Pharmacology and Study Measures

Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.

After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.

Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.

Background and Receptor Pharmacology

Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.

Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.

Background from the literature

Aberrant activation of Akt, either via PI3K or independently of PI3K, is often associated with malignancy. Studies have identified gene amplification of the Akt isoforms in many types of cancer, including glioblastoma, ovarian, pancreatic and breast cancers. Akt is also up-regulated in terms of mRNA production in breast and prostate cancer. Functional inactivation of PTEN, the major PI3K antagonist, can occur in cancer cells by point mutation, gene deletion or epigenetic mechanisms. Mutation in the pathway can also affect receptor tyrosine kinases, growth factors, Ras and the PI3K p110 subunit, leading to abnormal signaling activity. Therefore, many of the proteins in the pathway are targets for cancer therapeutics. In addition to its effects on cell survival and cell cycle progression, the PI3K-Akt pathway promotes other characteristics of cancer cells. Hyperactivity of the pathway promotes the epithelial-mesenchymal transition (EMT) and metastasis due to its effects on cell migration.

Wide range of genomic applications and scientific questions, including de novo genome assembly, haplotype phasing, structural variant analysis, and transcriptome and epigenetic analysis. Accuracy and scalability. Method requires small quantities of input DNA, which can be beneficial for small samples or single cell studies. More cost effective per sample in comparison with long-read technologies such as Oxford Nanopore sequencing. Libraries produced by linked-read can be processed using Illumina short read sequencing, increasing accessibility. Complexity of library construction - this technology requires high molecular DNA preparation in order to produce long enough DNA molecules for sequencing. Limitations in read length may result in limited haplotype resolution, which could reduce the efficacy of this technology in highly complex genomic regions.

2 Bh + 3 O2 + 2 HCl → 2 BhO3Cl + H2 The longer-lived heavy isotopes of bohrium, produced as the daughters of heavier elements, offer advantages for future radiochemical experiments. Although the heavy isotope 274Bh requires a rare and highly radioactive berkelium target for its production, the isotopes 272Bh, 271Bh, and 270Bh can be readily produced as daughters of more easily produced moscovium and nihonium isotopes.

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. The most frequently reported side effect is hypoglycemia (low blood glucose levels). It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.

In July 2009, Mohammad Sajjadur Rahman noted that Russia's role in the Caucasus region in the 1990s "transformed the separatist conflicts into a dispute between Georgia and Russia" and that "Realism, the most dominant theory of International Relations, can be applied in analyzing Russian behavior" in the conflict which was the first Russian military action since the Soviet–Afghan War. Rahman denied the claim that Russia was defending itself, explaining that "long before the war broke out, Russia had established the infrastructure and logistical support for a military invasion" and decision to go to war was "guided by a number of geopolitical interests that Russia sought to advance through a decisive victory", such as "Putins’ evident desire to elevate Russia's Great Power image". However, "the war exposed Russia's failure to accomplish political objectives without recourse to violence." Rahman summarized that "the causes of the August war were indeed complex and multifaceted" and the failure of the West "in deescalating the tension also contributed to the outbreak of this limited war."

Sources: en.wikipedia.org

Reference notes

As of 2010, there was widespread controversy over the use of human embryonic stem cells. This controversy primarily targets the techniques used to derive new embryonic stem cell lines, which often requires the destruction of the blastocyst. Opposition to the use of human embryonic stem cells in research is often based on philosophical, moral, or religious objections. There is other stem cell research that does not involve the destruction of a human embryo, and such research involves adult stem cells, amniotic stem cells, and induced pluripotent stem cells. In January 2009, the US Food and Drug Administration gave clearance to Geron Corporation for the first clinical trial of an embryonic stem-cell-based therapy on humans. The trial aimed to evaluate the drug GRNOPC1, embryonic stem cell-derived oligodendrocyte progenitor cells, on people with acute spinal cord injury. The trial was discontinued in November 2011 so that the company could focus on therapies in the "current environment of capital scarcity and uncertain economic conditions". In 2013 biotechnology and regenerative medicine company BioTime (AMEX: BTX) acquired Geron's stem cell assets in a stock transaction, with the aim of restarting the clinical trial.

The new constitution, proclaiming a democratic republic, direct universal suffrage, and the separation of powers, was promulgated on 4 November 1848. Under the new constitution, there was to be a single permanent Assembly of 750 members elected for a term of three years by the scrutin de liste. The Assembly would elect members of a Council of State to serve for six years. Laws would be proposed by the Council of State, to be voted on by the Assembly. The executive power was delegated to the president, who was elected for four years by direct universal suffrage, i.e. on a broader basis than that of the Assembly, and was not eligible for re-election. He was to choose his ministers, who, like him, would be responsible to the Assembly. Revision of this constitution was made practically impossible: it involved obtaining three times in succession a majority of three-quarters of the deputies in a special assembly. It was in vain that Jules Grévy—on behalf of those who perceived the obvious and inevitable risk of creating, under the name of a president, a monarch and indeed one who was more than a king at that—proposed that the head of the state should be no more than a removable president of the ministerial council. Lamartine, thinking that he was sure to be the choice of the electors under universal suffrage, won over the support of the Chamber, which did not even take the precaution of rendering ineligible the members of families which had reigned over France. It made the presidency an office dependent upon popular acclamation.

14 June Vodafone and Three announce a merger, pending approval from regulators, to create the largest mobile company in the UK. Thousands of people gather for a vigil to mourn the victims of the attacks in Nottingham. Police continue questioning a suspect, as the BBC obtains CCTV footage of a man believed to be the perpetrator. Researchers at the University of Cambridge report the creation of the first synthetic human embryo from stem cells, without the need for sperm or egg cells. 15 June Partygate: A 13-month investigation by the House of Commons' Privileges Committee concludes that ex-Prime Minister Johnson deliberately misled the Commons over gatherings during pandemic restrictions at 10 Downing Street and Chequers. The report proposes that he would be suspended for 90 days if still an MP. It states that he deliberately misled the House and the committee, impugned the committee and was "complicit in the campaign of abuse and attempted intimidation of the Committee". The Parole Board announces that double child killer and rapist Colin Pitchfork has been granted parole and will be released from prison. Alberto Costa, MP for South Leicestershire where the girls were killed, writes to the Justice Secretary to seek "an immediate and urgent review" of the decision. 16 June A hosepipe and sprinkler ban is announced for Kent and Sussex, beginning on 26 June, after water demand hits record levels.

P-ATPases (sometime known as E1-E2 ATPases) are found in bacteria and also in eukaryotic plasma membranes and organelles. Its name is due to short time attachment of inorganic phosphate at the aspartate residues at the time of activation. Function of P-ATPase is to transport a variety of different compounds, like ions and phospholipids, across a membrane using ATP hydrolysis for energy. There are many different classes of P-ATPases, which transports a specific type of ion. P-ATPases may be composed of one or two polypeptides, and can usually take two main conformations, E1 and E2.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does PT-141 act on?

Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.

Does PT-141 act by increasing blood flow?

It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.

Why is the mechanism described as uncertain?

Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.

Why are peptide standards stored at low temperature?

Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.

Network